SEC Tracker
Get the app

Maze Therapeutics MAZE

Maze Therapeutics reports Q3 2026 financial results

Maze Therapeutics (MAZE) filed an 8-K with the SEC on Nov 9, 2026, 4:10 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities were $477 million as of September 30, 2026.
  2. License revenue of $20 million recognized for the three months ended September 30, 2026.
  3. R&D expenses for the three months ended September 30, 2026 were $40.2 million.
  4. Enrollment completed in Phase 2 HORIZON trial of MZE829 with over 50 patients.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Maze Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.